TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05202509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to resemble obicetrapib
Study: NCT06110910
Drug: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
Study: NCT05644301
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule, 200 mg, twice daily, for 12 weeks
Study: NCT05644301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, no active substance, twice daily, for 12 weeks
Study: NCT06076135
Drug: PD-1/PD-L1 Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
Study: NCT06422247
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
Study: NCT04912518
Drug: Placebo (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
Study: NCT06083571
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-inferiority
Study: NCT06644326
Drug: 100mg IkT-148009 Wet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg wet tablet formulation
Study: NCT05803772
Drug: APHD-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
Study: NCT05803772
Drug: APH-012P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal jejunal-release placebo beads
Study: NCT06226766
Drug: JSKN033 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
Study: NCT05348122
Drug: TG103,Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Study: NCT05348122
Drug: TG103,QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study: NCT05348122
Drug: Placebo,Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Study: NCT05348122
Drug: Placebo,QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study: NCT04976855
Drug: INDV-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration
Study: NCT04976855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration
Study: NCT04976855
Drug: SUBOXONE® sublingual film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
Study: NCT05444439
Drug: empirical H.pylori regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
Study: NCT06673641
Drug: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Study: NCT06673641
Drug: CABTREO Topical Gel
Normalized name: Cabtreo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Study: NCT06673641
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
Study: NCT06675422
Drug: JY231 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.
Study: NCT05772156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching saline placebo
Study: NCT03984188
Drug: Theophylline ER
Normalized name: Theophylline ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg extended release (ER) low-dose theophylline taken orally daily
Study: NCT03984188
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured methylcellulose placebo tablet taken orally daily
Study: NCT05998759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous placebo weekly for 24 weeks.
Study: NCT05720091
Drug: ZX-7101A 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: a drug to treatment influenza in Chinese adults
Study: NCT06534723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04741074
Drug: Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
Study: NCT05647473
Drug: add-on low dose Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an additional 10g of astragalus per day.
Study: NCT05647473
Drug: add-on high dose Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an additional 20g of astragalus per day.
Study: NCT05379946
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN10018 orally once daily at approximately the same time each day
Study: NCT06096220
Drug: Application of 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
Study: NCT06303752
Drug: ADRC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
Study: NCT06303752
Drug: ADRC001 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
Study: NCT06155331
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline derived chemotherapy used in treatment of breast cancer
Study: NCT06155331
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent used in treatment of breast cancer
Study: NCT04994990
Drug: OnabotulinumtoxinA Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
Study: NCT04994990
Drug: OnabotulinumtoxinA Half Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
Study: NCT06090799
Drug: SHR-3032 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose at varying dosage levels depending on treatment assignment
Study: NCT05711797
Drug: ZX-7101A 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX-7101A a drug to treatment influenza in Chinese adults
Study: NCT06088043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified drug on specified days.
Study: NCT05284617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05003076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT06290713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
Study: NCT04909333
Drug: 0.9% saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously.
Study: NCT06024421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light yellow, film-coated tablet
Study: NCT06493396
Drug: Opioid-free Analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Study: NCT05797623
Drug: Trappa ethanolamine tablets ; ciclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trappa ethanolamine tablets combined with ciclosporin
Study: NCT05797623
Drug: Placebo ; ciclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with ciclosporin
Study: NCT03970031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablet
Study: NCT06288893
Drug: SHEN211 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
Study: NCT06493396
Drug: Opioid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Study: NCT06639230
Drug: Sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
Study: NCT05954624
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT05954624
Drug: ZSP1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04998513
Drug: Medical Management Alone Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group.
Study: NCT05384483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05824728
Drug: AGB101
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose levetiracetam, 220 mg, extended release tablet
Study: NCT04965064
Drug: Capecitabine and Neratinib.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
Study: NCT06644794
Drug: Hormone replacement therapy cycle preparation for frozen embryo transfer
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
Study: NCT04782375
Drug: Stop group
Approvals — FDA: no, EMA: no, PMDA: no
Description: discontinue antiviral treatment
Study: NCT05823441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers inhale 24 units of placebo spray
Study: NCT05299424
Drug: CM336_group 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 2a
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 2b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 3a
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 3b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 4a
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 4b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 5
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 6a
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 6b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 7
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 8a
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 8b
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_group 9
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05299424
Drug: CM336_RP2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
Study: NCT05462262
Drug: Intensive lipid-lowering control
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
Study: NCT05462262
Drug: Moderate-intensity lipid-lowering control
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
Study: NCT05021835
Drug: Placebo (Ziltivekimab B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Study: NCT05021835
Drug: Placebo (Ziltivekimab C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Study: NCT03066739
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 micrograms/kg/mL
Study: NCT03066739
Drug: Remifentanil+ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
Study: NCT03066739
Drug: Remifentanil +ultra-low dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
Study: NCT06381791
Drug: Placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg of Placebo oral solution
Study: NCT06381960
Drug: Fuzhengquye Fang Recipe simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.